Join us at the World Orphan Drug Congress Europe where our team will share insights into how rare disease companies can navigate European launch, access and commercialisation more effectively. Through discussions on tailored commercial models, early access, market readiness, patient engagement and launch sequencing, this pivotal event brings together global leaders to explore how innovation, partnership and practical support can help bring rare disease therapies to patients across Europe.
Meet the Sciensus team at the World Orphan Drug Congress Europe
Our speaking sessions
Date: 26th October Time: 11:30 – 13:00
Speakers:
- TBC
TBC
Date: 26th October Time: 11:30 – 13:00
Speakers:
- TBC
European launch and access expertise
Leveraging over 30 years of clinical experience, deep therapeutic expertise and personalised digital innovation, we help rare disease companies bring treatments to patients across Europe faster.
Expertise that makes the difference
Leveraging over 30 years of clinical experience, deep therapeutic expertise and personalised digital innovation, we help biopharma, CROs and CCOs bring treatments to patients across Europe faster.
$ 380,000,000 +
orphan drugs bought and sold per year
0
relationships with healthcare providers
0 +
units of orphan medicine supplied
Get a faster route into Europe
Request a meeting for a focused strategic conversation on your asset, where we’ll explore how you can accelerate access to Europe by using one integrated partner for end-to-end support.